Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

The aim of these guidelines is to provide practical clinical guidance and recommendations to clinicians to manage diffuse large B-cell lymphomas (DLBCLs) that arise in extranodal sites. DLBCL may arise in virtually any extranodal sites, but the majority of these are treated as the nodal counterpart, i.e. gastric DLBCL. For the recommended treatment, the reader can refer to the 2015 ESMO DLBCL guidelines [1]. The choice of the entities included in these guidelines is based on the clinical need to give recommendations for those entities which require a specific therapeutic approach. Recommendations for primary cutaneous DLBCL have been already reported by ESMO